AI News
AI biotech Isomorphic Labs is not slowing down, exec says
Isomorphic Labs doubles down on internal model security to accelerate breakthrough drug discovery.
“All of our AI models are locked down and locked down in-house,” Chris Butler, who runs drug discovery at the Google-backed drug company, said at Semafor’s Future of Health Forum.
ST
Semafor Tech
Source
Semafor Tech
AI Analysis
Generated insight by OnAirToday AI
By internalizing their model training and security, Isomorphic Labs is prioritizing proprietary intellectual property in the competitive race for AI-driven drug discovery. This strategy reflects a broader industry shift toward 'closed-garden' pharmaceutical development to prevent data leakage and maintain a competitive edge.
Powered by AI • Not a substitute for human analysisMore Insights →
Share
Filed under:AI News
Comments
Keep comments relevant and respectful. No links, advertising, self-promotion, or spam.